Promaxo 'excited to expand our presence' with new office in Belgium

Technology
Pexels sora shimazaki 5673488
Promaxo Inc. recently hired Pete Zaudtke as the head of its European office. | Sora Shimazaki/ Pexels

California medical tech company Promaxo Inc. recently hired Pete Zaudtke as the head of its European office amid an overseas expansion and launch of a Belgium site, a news release said.

"We are excited to expand our presence and enter Europe, with the opening of Promaxo BV, headquartered in Bruges, Belgium," Promaxo Founder and CEO Dr. Amit Vohra said. "From this launching pad, we look forward to initiating clinical studies and developing regulatory, as well as commercial pathways, to provide European physicians and centers with access to our portable MRI system for point-of-care diagnostic biopsies and treatment of cancers, driving a shift to in-office diagnostic and treatment procedures."

The executive has more than 15 years of international life sciences experience, which he will use to spearhead and prioritize Promaxo's entry into Europe and take on his new leadership role, the release said. 

Zaudtke's experience includes heading an international life sciences advisory firm where he has been able to boost growth to record levels. He previously launched a U.S./Dutch oncology company where he worked as chief financial officer, vice president of operations.

"I am thrilled with the opportunity to lead Promaxo BV and the company's entry into Europe. This is a very exciting time for Promaxo, with its Federal Drug Administration-approved single sided, AI-enhanced imaging system for prostate cancer," Zaudtke said in a release. "We have a platform that represents the possibility for diagnostic biopsy and treatment in multiple indications paired with a strong commitment from Promaxo leadership to bring this technology to physicians and patients in Europe."

Part of the initiative includes undergoing clinical studies that provide access to the company's portable MRI system, leading to the development of point-of-care diagnostic biopsies and cancer treatments.